flmly Message Board - Msg: 13390682

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : flmly

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: thomas a. burke who wrote (1)	4/10/2000 5:15:00 PM
From: opalapril	Read Replies (1) of 11

Flamel: Pipeline Potential (excerpt - Evan Sturza, Medical Investment Newsletter ) "Flamel's Micropump technology is for the controlled-release of pharmaceuticals in the small intestine and can be applied to the delivery of almost all available oral pharmaceuticals. It is validated by Genvir, the company's form of acyclovir for the treatment of genital herpes. In second quarter 2000, we expect Flamel to announce a marketing partner for the drug, and to file for regulatory approval in Europe by third quarter 2000. The current European market for anti-herpes drugs is estimated at over $400 million; we believe Genvir could achieve a 10% share in its second year on the market. Likely to be profitable in 2001, we feel the stock is substantially undervalued. Based on our 2002 earnings per share estimate of $0.48, we recommend Flamel as a strong buy. Our one-year target is $20." marketcentral.net

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next